American Pharmaceutical Partners Adds to Its Broad Oncology Portfolio with the Approval of Mitoxantrone Injection, USP (FinanzNachrichten)
American Pharmaceutical Partners, Inc. (NASDAQ:APPX) (APP), a leading specialty injectable pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Mitoxantrone Injection, USP (Concentrate), the generic equivalent of Serono Labs' Novantrone(R). According to IMS, sales in 2005 of

Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, (FinanzNachrichten)
SOUTH SAN FRANCISCO, Calif., April 11 /PRNewswire-FirstCall/ -- Genentech, ( Nachrichten ) Inc. announced today that the company submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) in combination with platinum-based chemotherapy for first-line treatment of advanced, non- squamous, non-small cell lung cancer